Development of PROSTVAC immunotherapy in prostate cancer

Parminder Singh, Sumanta K. Pal, Anitha Alex, Neeraj Agarwal

Research output: Contribution to journalArticlepeer-review

30 Scopus citations


PROSTVAC immunotherapy is a heterologous prime-boost regimen of two different recombinant pox-virus vectors; vaccinia as the primary immunotherapy, followed by boosters employing fowlpox, to provoke immune responses against prostate-specific antigen. Both vectors contain transgenes for prostate-specific antigen and a triad of T-cell costimulatory molecules (TRICOM). In a placebo-controlled Phase II trial of men with minimally symptomatic, chemotherapy-naive metastatic castration-resistant prostate cancer, PROSTVAC was well tolerated and associated with a 44% reduction in death. With a novel mechanism of action, and excellent tolerability, PROSTVAC has the potential to dramatically alter the treatment landscape of prostate cancer, not only as a monotherapy, but also in combination with other novel agents, such as immune check point inhibitors and novel androgen receptor blockers. A Phase III trial recently completed accrual.

Original languageEnglish (US)
Pages (from-to)2137-2148
Number of pages12
JournalFuture Oncology
Issue number15
StatePublished - Aug 1 2015


  • pox virus immunotherapy
  • prostate cancer

ASJC Scopus subject areas

  • Oncology
  • Cancer Research


Dive into the research topics of 'Development of PROSTVAC immunotherapy in prostate cancer'. Together they form a unique fingerprint.

Cite this